Supernus Pharmaceuticals, Inc. (SUPN) – What Are Brokerages Thinking About This Stock?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has received an average rating of “Hold” from the six brokerages that are presently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and three have given a buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $62.40.

A number of brokerages have recently weighed in on SUPN. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Monday, September 21st. Zacks Research cut Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Monday, October 5th. Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, Cantor Fitzgerald lifted their price objective on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a research note on Thursday, July 9th.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Ellsworth Advisors LLC increased its stake in shares of Supernus Pharmaceuticals by 3.4% in the 3rd quarter. Ellsworth Advisors LLC now owns 18,121 shares of the specialty pharmaceutical company’s stock valued at $780,000 after acquiring an additional 601 shares in the last quarter. Juncture Wealth Strategies LLC lifted its position in shares of Supernus Pharmaceuticals by 5.8% during the 3rd quarter. Juncture Wealth Strategies LLC now owns 6,778 shares of the specialty pharmaceutical company’s stock valued at $292,000 after acquiring an additional 374 shares during the period. Versant Capital Management Inc lifted its position in shares of Supernus Pharmaceuticals by 47.2% during the 3rd quarter. Versant Capital Management Inc now owns 1,503 shares of the specialty pharmaceutical company’s stock valued at $65,000 after acquiring an additional 482 shares during the period. Engineers Gate Manager LP bought a new position in Supernus Pharmaceuticals during the second quarter worth $1,119,000. Finally, Allworth Financial LP grew its stake in shares of Supernus Pharmaceuticals by 8.8% in the 2nd quarter. Allworth Financial LP now owns 50,669 shares of the specialty pharmaceutical company’s stock valued at $2,357,000 after buying an additional 4,111 shares during the period.

Supernus Pharmaceuticals Stock Up 5.2%

Supernus Pharmaceuticals stock opened at $39.84 on Tuesday. The company’s 50-day moving average price is $43.61 and its two-hundred day moving average price is $46.29. The stock has a market cap of $2.32 billion, a P/E ratio of -20.75, a P/E/G ratio of 0.97 and a beta of 0.55. Supernus Pharmaceuticals has a twelve month low of $37.54 and a twelve month high of $59.68.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.42 by ($1.43). Supernus Pharmaceuticals had a positive return on equity of 11.13% and a negative net margin of 13.23%. The firm had revenue of $219.06 million for the quarter, compared to the consensus estimate of $205.31 million. During the same quarter in the prior year, the firm earned $0.40 EPS. The company’s revenue was up 32.4% on a year-over-year basis. Equities analysts anticipate that Supernus Pharmaceuticals will post 2.05 earnings per share for the current fiscal year.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for diseases of the central nervous system (CNS). The company’s portfolio has primarily addressed epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on differentiated formulations and products designed to improve treatment convenience and patient outcomes.

Supernus markets Oxtellar XR (oxcarbazepine extended-release) for the treatment of partial-onset seizures and Trokendi XR (topiramate extended-release) for certain seizure disorders and the prevention of migraine headaches.